Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07296809 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SKB500 Combinations in Patients With Small Cell Lung Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv4
  2. Recruitment opened Start date changed from estimate of Dec 20, 2025 to Jan 30, 2026 · Site details revisedv3 Show 2 more changesShow less
    • Start date changed from estimate of Dec 20, 2025 to Jan 30, 2026
    • Site details revised
  3. Interventions: Carboplatin (Drug), Etoposide (Drug), PD-L1 inhibitor (Drug), SKB500 (Drug) to Carboplatin Injection (Drug), Etoposide Injection (Drug), KL-A167 Injection (Drug), SKB500 Powder for Injection (Drug)v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the safety, tolerability and preliminary antitumor activity of SKB500 combinations in patients with small cell lung cancer. The study is divided into two parts. Part 1 will be the safety run-in phase, and Part 2 will be the cohort expansion phase.
Trial Details
NCT Number NCT07296809
Lead Sponsor Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Conditions Small Cell Lung Cancer
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov